Executive Summary#

Guidance Raise Signals Durable Execution#

Stryker Corporation's second-quarter 2025 earnings delivered a dual message of operational excellence and capital discipline that has vindicated management's strategic positioning at SYK. The medical-device manufacturer raised its full-year 2025 guidance—projecting organic revenue growth of 9.5 to 10 per cent, up from prior guidance of 8 to 9 per cent, and adjusted earnings per share of US$13.40 to US$13.60, versus prior guidance of US$13.20 to US$13.45—signalling that the company's margin-expansion thesis is not merely aspirational but executable across cycles. This is no trivial reassurance in an era when medtech companies face persistent headwinds from tariffs, foreign exchange volatility, and integration risks from acquisitions. Stryker has instead demonstrated that disciplined operational management and prudent capital deployment can deliver compounding shareholder value.